特发性肺纤维化患者中阻塞性睡眠呼吸暂停的患病率及预后意义：一项前瞻性队列研究
Prevalence and prognostic significance of obstructive sleep apnea in patients with idiopathic pulmonary fibrosis: A prospective cohort study.
文献信息
| PMID | 42936363 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Hasibe Çigdem Erten |
| 作者单位 | Department of Chest Diseases, Kartal Dr. Lütfi Kırdar City Hospital, University of Health Sciences, Istanbul, Türkiye. |
| 期刊 | Annals of thoracic medicine |
| SCI 分区 | Q3 |
| IF | 2.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 鼻科 |
中文摘要
背景： 阻塞性睡眠呼吸暂停（OSA）是特发性肺纤维化（IPF）公认的合并症；然而，其真实患病率仍不确定，其预后意义也尚未完全阐明。本研究旨在确定IPF患者中OSA的患病率及危险因素，并评估其对疾病进展的影响。
方法： 本前瞻性研究纳入了在一家三级医疗中心随访的50例IPF患者。所有患者均接受多导睡眠监测（PSG），并将OSA分为轻度、中度或重度。在PSG前实施柏林问卷和Epworth嗜睡量表。在基线和1年时测量用力肺活量（FVC）和肺一氧化碳弥散量（DLCO）。疾病进展定义为FVC下降≥10%和/或DLCO下降≥15%。
结果： 平均年龄为67.8 ± 6.7岁，80%为男性。OSA患病率为90.0%（95%置信区间：78.2-96.7），轻度、中度和重度疾病各占30%的患者。中度至重度OSA与显著更大的肺功能下降相关（P = 0.030）。高血压和柏林问卷高风险状态与OSA的存在显著相关。
结论： IPF中OSA患病率极高，且大多数为中重度疾病。柏林问卷可作为该人群中PSG适应资格的可靠筛查工具。这些发现提示OSA可能促进IPF患者的功能性疾病的进展。
英文摘要
BACKGROUND: Obstructive sleep apnea (OSA) is a recognized comorbidity in idiopathic pulmonary fibrosis (IPF); however, its true prevalence remains uncertain, and its prognostic implications have not been fully elucidated. This study aimed to determine the prevalence of and risk factors for OSA in patients with IPF and to evaluate its impact on disease progression.
METHODS: This prospective study enrolled 50 patients with IPF followed at a tertiary care center. All patients underwent polysomnography (PSG), and OSA was classified as mild, moderate, or severe. The Berlin Questionnaire and the Epworth Sleepiness Scale were administered prior to PSG. Forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) were measured at baseline and at 1 year. Disease progression was defined as a ≥10% decline in FVC and/or a ≥15% decline in DLCO.
RESULTS: The mean age was 67.8 ± 6.7 years, and 80% were male. OSA prevalence was 90.0% (95% confidence interval: 78.2-96.7), with mild, moderate, and severe disease each present in 30% of patients. Moderate-to-severe OSA was associated with significantly greater pulmonary function decline (P = 0.030). Hypertension and high-risk status on the Berlin Questionnaire were significantly associated with the presence of OSA.
CONCLUSIONS: OSA prevalence in IPF is remarkably high, with the majority having moderate-to-severe disease. The Berlin Questionnaire may serve as a reliable screening tool for PSG candidacy in this population. These findings suggest that OSA may contribute to functional disease progression in patients with IPF.